QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History
In brief
Moderna’s record rally was quickly erased by a 25.69% slide, reflecting the high stakes of its first Phase 3 mRNA cancer therapy and the weight of its short‑interest profile.